Literature DB >> 11459894

Transcranial magnetic stimulation studies in the Miller Fisher syndrome: evidence of corticospinal tract abnormality.

Y L Lo1, P Ratnagopal.   

Abstract

OBJECTIVES: To evaluate serial central motor conduction time in the Miller Fisher syndrome.
METHOD: Three patients with classic Miller Fisher syndrome were evaluated clinically. They had serial central motor conduction times measured with transcranial magnetic stimulation and nerve conduction studies. Motor evoked potentials were recorded from the first dorsal interossei and abductor hallucis muscles.
RESULTS: All three patients showed reduction in central motor conduction times in tandem with gradual clinical improvement at each review.
CONCLUSIONS: There is electrophysiological evidence of a central reversible corticospinal tract conduction abnormality in the Miller Fisher syndrome.

Entities:  

Mesh:

Year:  2001        PMID: 11459894      PMCID: PMC1737528          DOI: 10.1136/jnnp.71.2.210

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  29 in total

1.  Reversible proximal conduction block underlies rapid recovery in Guillain-Barré syndrome.

Authors:  A R Berger; E L Logigian; B T Shahani
Journal:  Muscle Nerve       Date:  1988-10       Impact factor: 3.217

2.  Abnormalities in central motor pathway conduction in multiple sclerosis.

Authors:  J M Cowan; J C Rothwell; J P Dick; P D Thompson; B L Day; C D Marsden
Journal:  Lancet       Date:  1984-08-11       Impact factor: 79.321

3.  The physiological basis for symptoms in Guillain-Barré syndrome.

Authors:  A J Sumner
Journal:  Ann Neurol       Date:  1981       Impact factor: 10.422

4.  Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study.

Authors:  A N Al-Din; M Anderson; E R Bickerstaff; I Harvey
Journal:  Brain       Date:  1982-09       Impact factor: 13.501

5.  Detection of serum anticerebellar antibodies in patients with Miller Fisher syndrome.

Authors:  A Inoue; C Koh; T Iwahashi
Journal:  Eur Neurol       Date:  1999       Impact factor: 1.710

Review 6.  [Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies].

Authors:  S Kusunoki
Journal:  Rinsho Shinkeigaku       Date:  1999-01

7.  Miller Fisher syndrome: clinical and electrophysiologic evidence of peripheral origin in 10 cases.

Authors:  B Sauron; P Bouche; H P Cathala; F Chain; P Castaigne
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Electrophysiologic studies in Miller Fisher syndrome.

Authors:  G A Jamal; W N MacLeod
Journal:  Neurology       Date:  1984-05       Impact factor: 9.910

9.  [Electrophysiological and morphological effects of the injection of Guillain-Barré sera in the sciatic nerve of the rat (author's transl)].

Authors:  A Sumner; G Said; I Idy; S Metral
Journal:  Rev Neurol (Paris)       Date:  1982       Impact factor: 2.607

10.  The localization of the lesion in patients with acute ophthalmoplegia, ataxia and areflexia (Miller Fisher syndrome). A serial multimodal neurophysiological study.

Authors:  G A Jamal; J P Ballantyne
Journal:  Brain       Date:  1988-02       Impact factor: 13.501

View more
  3 in total

1.  Acute ophthalmoparesis in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculi.

Authors:  Y L Lo; L L Chan; A Pan; P Ratnagopal
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

2.  Cutaneous silent periods in the evaluation of cord compression in cervical spondylosis.

Authors:  Y L Lo; Y E Tan; Y F Dan; T H Leoh; S B Tan; C T Tan; L L Chan
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

3.  Cortical Reorganization Is Associated with Surgical Decompression of Cervical Spondylotic Myelopathy.

Authors:  Andrew Green; Priscilia W T Cheong; Stephanie Fook-Chong; Rajendra Tiruchelvarayan; Chang Ming Guo; Wai Mun Yue; John Chen; Yew Long Lo
Journal:  Neural Plast       Date:  2015-11-02       Impact factor: 3.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.